Suppr超能文献

日本两个真实世界数据库(医学数据视野和日本医学数据中心)在日本的使用背景及考量因素

Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data Center.

作者信息

Laurent Thomas, Simeone Jason, Kuwatsuru Ryohei, Hirano Takahiro, Graham Sophie, Wakabayashi Ryozo, Phillips Robert, Isomura Tatsuya

机构信息

Clinical Study Support Inc., 2F Daiei Bldg., 1-11-20 Nishiki, Naka-ku, Nagoya, 460-0003, Japan.

Fifth Floor, Real-World Evidence, Evidera, 500 Totten Pond Road, Waltham, MA, 02451, USA.

出版信息

Drugs Real World Outcomes. 2022 Jun;9(2):175-187. doi: 10.1007/s40801-022-00296-5. Epub 2022 Mar 18.

Abstract

In Japan, an increasing interest in real-world evidence for hypothesis generation and decision-making has emerged in order to overcome limitations and restrictions of clinical trials. We sought to characterize the context and concrete considerations of when to use Medical Data Vision (MDV) and JMDC databases, the main Japanese real-world data (RWD) sources accessible by pharmaceutical companies. Use cases for these databases, and related issues and considerations, were identified and summarized based on a literature search and experience-based knowledge. Studies conducted using MDV or JMDC were mostly descriptive in nature, or explored potential risk factors by evaluating associations with a target outcome. Considerations such as variable ascertainment at different time points, including issues relating to treatment identification and missing data, were highlighted for these two databases. Although several issues were commonly shared (e.g., only month of event occurrence reported), some database-specific issues were also identified and need to be accounted for. In conclusion, MDV and JMDC present limitations that are relatively typical of RWD sources, though some of them are unique to Japan, such as the identification of event occurrence and the inability to track patients visiting different healthcare settings. Addressing study design and careful result interpretation with respect to the specificities and uniqueness of the Japanese healthcare system is of particular importance. This aspect is especially relevant with respect to the growing global interest of conducting RWD studies in Japan.

摘要

在日本,为克服临床试验的局限性和限制,人们对用于假设生成和决策的真实世界证据的兴趣日益浓厚。我们试图描述使用医学数据愿景(MDV)和JMDC数据库(制药公司可获取的主要日本真实世界数据(RWD)来源)的背景及具体考量因素。基于文献检索和经验知识,确定并总结了这些数据库的用例以及相关问题和考量因素。使用MDV或JMDC进行的研究大多本质上是描述性的,或者通过评估与目标结局的关联来探索潜在风险因素。针对这两个数据库,强调了不同时间点的变量确定等考量因素,包括与治疗识别和缺失数据相关的问题。尽管存在一些共同问题(例如,仅报告事件发生月份),但也识别出了一些特定于数据库的问题,需要加以考虑。总之,MDV和JMDC存在相对典型的RWD来源的局限性,尽管其中一些是日本特有的,例如事件发生的识别以及无法跟踪就诊于不同医疗机构的患者。针对日本医疗系统的特殊性和独特性进行研究设计并谨慎解释结果尤为重要。这一点在全球对在日本开展RWD研究的兴趣日益浓厚的背景下尤为相关。

相似文献

4
A Review of Research Studies Using Data from the Administrative Claims Databases in Japan.一项利用日本行政索赔数据库数据的研究综述
Drugs Real World Outcomes. 2022 Dec;9(4):543-550. doi: 10.1007/s40801-022-00331-5. Epub 2022 Sep 15.

引用本文的文献

本文引用的文献

4
Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan.日本新冠疫情期间哮喘住院治疗趋势。
J Allergy Clin Immunol Pract. 2021 Jan;9(1):494-496.e1. doi: 10.1016/j.jaip.2020.09.060. Epub 2020 Oct 14.
7
Cancer genomic medicine in Japan.日本的癌症基因组医学。
Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(7):316-321. doi: 10.2183/pjab.96.023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验